keyword
MENU ▼
Read by QxMD icon Read
search

Radiotherapy vaccine

keyword
https://www.readbyqxmd.com/read/30324354/immunodiagnostics-and-immunotherapy-possibilities-for-prostate-cancer
#1
Heide Schatten
Despite significant progress in early detection and improved treatment modalities prostate cancer remains the second leading cause of cancer death in American men which results in about 30,000 deaths per year in the USA. An aggressive phenotype leading to 2.58% risk of dying from prostate cancer still exists and immunotherapy has offered new possibilities to treat metastatic prostate cancer that cannot be treated by other modalities. Cancer immunotherapy is a rapidly growing field of research aimed at identifying biomarkers in immunodiagnosis and to develop new therapies by enabling the immune system to detect and destroy cancer cells...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/30311576/immunotherapy-for-ebv-associated-nasopharyngeal-carcinoma
#2
Mengying Hong, Kejun Tang, Jing Qian, Hongyu Deng, Musheng Zeng, Shu Zheng, Kefeng Ding, Yushen Du, Ren Sun
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease. 1-5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy...
2018: Critical Reviews in Oncogenesis
https://www.readbyqxmd.com/read/30311129/monoclonal-antibodies-in-cancer-immunotherapy
#3
REVIEW
Ilgin Kimiz-Gebologlu, Sultan Gulce-Iz, Cigir Biray-Avci
Nowadays, in cancer treatments, immunotherapy which can be classified as a cancer type specific therapy is more popular than non-specific therapy methods such as surgery, radiotherapy and chemotherapy. The main aim of immunotherapy is to enable patients' immune system to target cancer cells and destroy them. The mainly used treatment methods in cancer immunotherapy are cancer vaccines, adoptive cell therapy, cytokines and monoclonal antibodies. In this review, we discuss the immunotherapy approaches, especially monoclonal antibodies which are mostly used in cancer immunotherapy in clinical applications...
October 11, 2018: Molecular Biology Reports
https://www.readbyqxmd.com/read/30295097/combination-treatment-of-advanced-pancreatic-cancer-using-novel-vaccine-and-traditional-therapies
#4
Hiroto Matsui, Shoichi Hazama, Yoshitaro Shindo, Hiroaki Nagano
Pancreatic cancer is a highly malignant disease with high treatment resistance. Many patients are diagnosed in a very advanced state, and few patients can be curatively resected. With FOLFIRINOX and nab-paclitaxel plus gemcitabine, the prognosis of advanced pancreatic cancer has improved, yet many patients cannot survive longer than a year. Therefore, new therapeutic approaches are needed. Cancer vaccine therapy is characterized by controlling cancer by a cancer-specific immune reaction with few adverse events...
October 8, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/30254983/indoximod-an-immunometabolic-adjuvant-that-empowers-t-cell-activity-in-cancer
#5
REVIEW
Eric Fox, Thomas Oliver, Melissa Rowe, Sunil Thomas, Yousef Zakharia, Paul B Gilman, Alexander J Muller, George C Prendergast
Exploding interest in immunometabolism as a source of new cancer therapeutics has been driven in large part by studies of tryptophan catabolism mediated by IDO/TDO enzymes. A chief focus in the field is IDO1, a pro-inflammatory modifier that is widely overexpressed in cancers where it blunts immunosurveillance and enables neovascularization and metastasis. The simple racemic compound 1-methyl-D,L-tryptophan (1MT) is an extensively used probe of IDO/TDO pathways that exerts a variety of complex inhibitory effects...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/30237360/-the-pedigree-of-immuno-oncology-history-and-current-status-of-immunotherapy-against-malignancy
#6
Yasuyuki Sugiyama
Since 1970s immunotherapy had been thought to be one of feasible strategies against malignancy. During that time nonspecific immunotherapy by biological response modifiers(BRMs), peptide vaccine therapy, dendritic cell-based vaccine therapy, adoptive cell therapy, targeting therapy by use of monoclonal antibody, and so on, had been investigated but finally they resulted in disappointment because of inappropriate clinical trials followed by limited efficacy. Therefore the understanding of clinical oncologists in regard to immunotherapy had been considerably poor until 2010...
September 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/30198439/immunotherapy-in-patients-with-recurrent-and-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#7
Izabela Lasinska, Tomasz Kolenda, Anna Teresiak, Katarzyna M Lamperska, Lukasz Galus, Jacek Mackiewicz
Head and neck squamous cell carcinoma (HNSCC) is the most common malignant cancer occurring in the head and neck area, approximately 90% of the cases. Even in the cases of primary radical treatment (surgical, concomitant chemoradiotherapy or radiotherapy alone), local recurrence or distal metastases are often observed. In patients with recurrent disease who are unable to receive radical treatment, the results of palliative chemotherapy are not satisfactory. The breakthrough in the therapy of advanced HNSCC was the approval of cetuximab in combination with chemotherapy in 2008...
September 9, 2018: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/30191140/immuno-oncology-emerging-targets-and-combination-therapies
#8
REVIEW
Henry T Marshall, Mustafa B A Djamgoz
Host immunity recognizes and eliminates most early tumor cells, yet immunological checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to effective antitumor immune responses. T-lymphocyte co-inhibitory pathways influence intensity, inflammation and duration of antitumor immunity. However, tumors and their immunosuppressive microenvironments exploit them to evade immune destruction. Recent PD-1 checkpoint inhibitors yielded unprecedented efficacies and durable responses across advanced-stage melanoma, showcasing potential to replace conventional radiotherapy regimens...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/30186977/activation-of-immune-responses-in-patients-with-relapsed-metastatic-head-and-neck-cancer-confront-phase-i-ii-trial-multimodality-immunotherapy-with-avelumab-short-course-radiotherapy-and-cyclophosphamide
#9
Marco C Merlano, Anna M Merlotti, Lisa Licitra, Nerina Denaro, Elena Fea, Danilo Galizia, Massimo Di Maio, Claudia Fruttero, Paola Curcio, Stefania Vecchio, Elvio G Russi, Renzo Corvò
Introduction and background: Second-line treatment of platinum-resistant relapsed/metastatic (R/M) head and neck cancer (HNC) is a currently unmet clinical need. Clinical trials showed improvement in overall survival and quality of life of R/M-HNC patients treated with anti-PD-1 regardless of the number of prior chemotherapy lines; however, the percentage of long-term survivors remains limited.This study aims to test the hypothesis that attacking the tumor microenvironment at multiple levels can increase immunogenicity of R/M-HNC without worsening the safety profile of immune checkpoint inhibitors...
August 2018: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/30169990/selecting-immuno-oncology-based-drug-combinations-what-should-we-be-considering
#10
Lucia Festino, Vito Vanella, Claudia Trojaniello, Paolo A Ascierto
Checkpoint inhibitor immunotherapy has revolutionized the treatment of many advanced stage cancers. Preexisting immunity is necessary for a response to these agents, which are most effective in inflamed tumors since they principally act by reinforcing preexisting antitumor T-cell responses. An important goal of therapy is to convert the tumor environment from non-inflamed to inflamed in order to facilitate subsequent response to checkpoint inhibitors. Clinical trials are underway to identify checkpoint inhibitor-based combination approaches, which may help to achieve this goal...
October 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/30150597/therapeutic-immunization-against-glioblastoma
#11
REVIEW
Virgil E J C Schijns, Chrystel Pretto, Anna M Strik, Rianne Gloudemans-Rijkers, Laurent Deviller, Denis Pierre, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank P K Hsu, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Daniela A Bota, Apostolos Stathopoulos
Glioblastoma is the most common form of brain cancer in adults that produces severe damage to the brain leading to a very poor survival prognosis. The standard of care for glioblastoma is usually surgery, as well as radiotherapy followed by systemic temozolomide chemotherapy, resulting in a median survival time of about 12 to 15 months. Despite these therapeutic efforts, the tumor returns in the vast majority of patients. When relapsing, statistics suggest an imminent death dependent on the size of the tumor, the Karnofsky Performance Status, and the tumor localization...
August 27, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/30122953/effective-nivolumab-sequential-thoracic-radiotherapy-in-elderly-patients-with-advanced-squamous-cell-lung-cancer-did-radiation-therapy-play-a-role-a-case-report
#12
Grazia Lazzari, Angela Terlizzi, Giovanna Porrazzo, Salvatore Devicienti, Francesco Perri, Giuseppina Della Vittoria Scarpati, Giovanni Silvano
Advanced squamous cell lung carcinoma in elderly patients has a limited chance of cure with first, second line chemotherapy and radiotherapy. Radiotherapy in advanced non-small-cell lung cancer can be used with curative intent for localized or oligometastatic disease using standard or altered fractionations. Current evidence indicates that radiotherapy via diverse cascade mechanisms is able to invoke both local and systemic immunoresponses promoting tumor cell death through an in situ vaccination effect. Moreover, the advancement in immunotherapies is changing the scenario...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/30105016/radiation-induced-transformation-of-immunoregulatory-networks-in-the-tumor-stroma
#13
REVIEW
Inigo Martinez-Zubiaurre, Anthony J Chalmers, Turid Hellevik
The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represents a major advancement in the treatment of cancer, and has renewed enthusiasm for identifying new ways to induce antitumor immune responses in patients. Despite the proven efficacy of neutralizing antibodies that target immune checkpoints in some refractory cancers, many patients do not experience therapeutic benefit, possibly owing to a lack of antitumor immune recognition, or to the presence of dominant immunosuppressive mechanisms in the tumor microenvironment (TME)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29970573/prognostic-factors-for-pancreatic-cancer-patients-treated-with-immune-cell-therapy
#14
Kaori Makita, Takashi Kamigaki, Sachiko Okada, Eriko Matsuda, Hiroshi Ibe, Eri Oguma, Keiko Naitoh, Rishu Takimoto, Shigenori Goto
BACKGROUND/AIM: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. MATERIALS AND METHODS: The correlation between overall survival (OS) and various factors including sex, age, performance status (PS), distant metastasis, chemotherapy, radiotherapy, and type of immune-cell therapy were evaluated by univariate and multivariate analyses...
July 2018: Anticancer Research
https://www.readbyqxmd.com/read/29958629/therapeutic-vaccines-and-immune-checkpoints-inhibition-options-for-gynecological-cancers
#15
REVIEW
Chiara Di Tucci, Michele Carlo Schiavi, Pierangelo Faiano, Ottavia D'Oria, Giovanni Prata, Valentina Sciuga, Andrea Giannini, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici
Treatments for gynecological cancer include surgery, chemotherapy, and radiation. However, overall survival is not improved, and novel approaches are needed. Immunotherapy has been proven efficacious in various types of cancers and multiple approaches have been recently developed. Since numerous gynecological cancers are associated to human papilloma virus (HPV) infections, therapeutic vaccines, targeting HPV epitopes, have been developed. The advancing understanding of the immune system, regulatory pathways and tumor microenvironment have produced a major interest in immune checkpoint blockade, Indeed, immune checkpoint molecules are important clinical targets in a wide variety of tumors, including gynecological...
August 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29950117/emerging-patents-in-the-therapeutic-areas-of-glioma-and-glioblastoma
#16
REVIEW
Matthew Harris, Fredrik Svensson, Liliya Kopanitsa, Graham Ladds, David Bailey
Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma, with patients having a median survival of just over one year. Current chemotherapies, with surgery and radiotherapy, provide only minor patient benefit. There is a great need to discover and develop novel therapies for this devastating disease. Areas covered: The patent literature reveals novel therapies, providing insights into emerging GBM therapeutics. We have used the Google and USPTO patent databases to generate a detailed landscape of patents and patent applications from companies active in the areas of glioma and/or GBM...
July 2018: Expert Opinion on Therapeutic Patents
https://www.readbyqxmd.com/read/29907693/exosomes-shuttle-trex1-sensitive-ifn-stimulatory-dsdna-from-irradiated-cancer-cells-to-dcs
#17
Julie M Diamond, Claire Vanpouille-Box, Sheila Spada, Nils-Petter Rudqvist, Jessica R Chapman, Beatrix M Ueberheide, Karsten A Pilones, Yasmeen Sarfraz, Silvia C Formenti, Sandra Demaria
Radiotherapy (RT) used at immunogenic doses leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I) via the cGAS/STING pathway. Cancer cell-derived IFN-I is required to recruit BATF3-dependent dendritic cells (DC) to poorly immunogenic tumors and trigger antitumor T-cell responses in combination with immune checkpoint blockade. We have previously demonstrated that the exonuclease TREX1 regulates radiation immunogenicity by degrading cytosolic dsDNA...
August 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29893303/primary-pulmonary-synovial-sarcoma-a-reappraisal
#18
Manoj Kumar Panigrahi, Gourahari Pradhan, Nibedita Sahoo, Pritinanda Mishra, Susama Patra, Prasanta Raghab Mohapatra
Synovial sarcoma (SS) is a malignant mesenchymal tumor with variable epithelial differentiation that affects mostly young adults and can arise at any anatomic site. Primary intrathoracic SS is very rare accounting for <0.5% of all lung tumors. Most commonly, it arises from the lung followed by pleura and mediastinum. Primary pulmonary SS (PPSS) affects both sexes equally with no preference for any hemithorax. The morphology, immunostaining properties, cytogenetic features, and management strategy of PPSS are similar to that of soft tissue SS...
April 2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29862244/immune-checkpoint-inhibitors-and-radiotherapy-concept-and-review-of-current-literature
#19
REVIEW
Loka Thangamathesvaran, Roshni Shah, Rebeka Verma, Omar Mahmoud
Traditional chemotherapeutic agents non-selectively eliminate cancer cells at the expense of normal tissue; in an attempt to minimize such effects, a new class of targeted agents, immunotherapy, was introduced in the late 1950s with the discovery of interferons and the development of the first cancer vaccine. Ever since, immunotherapy evolved, exploiting different cellular mechanisms including dendritic cell therapy, monoclonal antibodies, and cytokines. Immune checkpoint inhibitors (ICPI) are the most recent subclass of this family and we herein review the basis of exploiting this new subclass of immunotherapy with radiotherapy in the context of studies evaluating their effects on human subjects and focusing on the synergism between the molecular pathways operating in the background...
April 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29843811/first-results-on-survival-from-a-large-phase-3-clinical-trial-of-an-autologous-dendritic-cell-vaccine-in-newly-diagnosed-glioblastoma
#20
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim, Charles S Cobbs, Jason A Heth, Michael Salacz, Sarah Taylor, Stacy D D'Andre, Fabio M Iwamoto, Edward J Dropcho, Yaron A Moshel, Kevin A Walter, Clement P Pillainayagam, Robert Aiken, Rekha Chaudhary, Samuel A Goldlust, Daniela A Bota, Paul Duic, Jai Grewal, Heinrich Elinzano, Steven A Toms, Kevin O Lillehei, Tom Mikkelsen, Tobias Walbert, Steven R Abram, Andrew J Brenner, Steven Brem, Matthew G Ewend, Simon Khagi, Jana Portnow, Lyndon J Kim, William G Loudon, Reid C Thompson, David E Avigan, Karen L Fink, Francois J Geoffroy, Scott Lindhorst, Jose Lutzky, Andrew E Sloan, Gabriele Schackert, Dietmar Krex, Hans-Jorg Meisel, Julian Wu, Raphael P Davis, Christopher Duma, Arnold B Etame, David Mathieu, Santosh Kesari, David Piccioni, Manfred Westphal, David S Baskin, Pamela Z New, Michel Lacroix, Sven-Axel May, Timothy J Pluard, Victor Tse, Richard M Green, John L Villano, Michael Pearlman, Kevin Petrecca, Michael Schulder, Lynne P Taylor, Anthony E Maida, Robert M Prins, Timothy F Cloughesy, Paul Mulholland, Marnix L Bosch
BACKGROUND: Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax® -L) to standard therapy for newly diagnosed glioblastoma. METHODS: After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding...
May 29, 2018: Journal of Translational Medicine
keyword
keyword
165426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"